{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:41:05Z","timestamp":1782762065717,"version":"3.54.5"},"reference-count":35,"publisher":"Pharmaceutical Society of Japan","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1248\/bpb.b17-00482","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T22:11:59Z","timestamp":1509487919000},"page":"1934-1940","source":"Crossref","is-referenced-by-count":33,"title":["Effects of the Antiepileptic Drugs Phenytoin, Gabapentin, and Levetiracetam on Bone Strength, Bone Mass, and Bone Turnover in Rats"],"prefix":"10.1248","volume":"40","author":[{"given":"Junkichi","family":"Kanda","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacotherapy, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Izumo","sequence":"additional","affiliation":[{"name":"General Health Medical Center, Yokohama University of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Radiation Science, Yokohama University of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Onodera","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacotherapy and Pharmacy, Bethel Epilepsy Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketoshi","family":"Shimakura","sequence":"additional","affiliation":[{"name":"Niigata Bone Science Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Niigata Bone Science Institute"},{"name":"Division of Orthopedic Surgery, Niigata Rehabilitation Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki E.","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Niigata Bone Science Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacotherapy, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Kotsopoulos IA, van Merode T, Kessels FG, de Krom MC, Knottnerus JA. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia<\/i>, 43<\/b>, 1402\u20131409 (2002).","DOI":"10.1046\/j.1528-1157.2002.t01-1-26901.x"},{"key":"2","unstructured":"2) Raisz LG. Physiology and pathophysiology of bone remodeling. Clin. Chem.<\/i>, 45<\/b>, 1353\u20131358 (1999)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science<\/i>, 289<\/b>, 1508\u20131514 (2000).","DOI":"10.1126\/science.289.5484.1508"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure<\/i>, 17<\/b>, 181\u2013186 (2008).","DOI":"10.1016\/j.seizure.2007.11.020"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Nissen-Meyer LS, Svalheim S, Tauboll E, Gjerstad L, Reinholt FP, Jemtland R. How can antiepileptic drugs affect bone mass, structure and metabolism? Lessons from animal studies. Seizure<\/i>, 17<\/b>, 187\u2013191 (2008).","DOI":"10.1016\/j.seizure.2007.11.024"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Swanton J, Simister R, Altmann D, Watts H, Keen R, Duncan JS, Koepp MJ. Bone mineral density in institutionalised patients with refractory epilepsy. Seizure<\/i>, 16<\/b>, 538\u2013541 (2007).","DOI":"10.1016\/j.seizure.2007.03.003"},{"key":"7","unstructured":"7) Nicholas JM, Ridsdale L, Richardson MP, Grieve AP, Gulliford MC. Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy: cohort study using the general practice research database. Seizure<\/i>, 22<\/b>, 37\u201342 (2013)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Mattson RH, Gidal BE. Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav.<\/i>, 5<\/b> (Suppl. 2), S36\u2013S40 (2004).","DOI":"10.1016\/j.yebeh.2003.11.030"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Sheth RD, Gidal BE, Hermann BP. Pathological fractures in epilepsy. Epilepsy Behav.<\/i>, 9<\/b>, 601\u2013605 (2006).","DOI":"10.1016\/j.yebeh.2006.08.003"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Takahashi A, Onodera K, Shinoda H, Mayanagi H. Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria. Jpn. J. Pharmacol.<\/i>, 82<\/b>, 82\u201384 (2000).","DOI":"10.1254\/jjp.82.82"},{"key":"11","unstructured":"11) Moro-Alvarez MJ, Diaz Curiel M, de la Piedra C, Marinoso ML, Carrascal MT. Bone disease induced by phenytoin therapy: clinical and experimental study. Eur. Neurol.<\/i>, 62<\/b>, 219\u2013230 (2009)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Reimers A. New antiepileptic drugs and women. Seizure<\/i>, 23<\/b>, 585\u2013591 (2014).","DOI":"10.1016\/j.seizure.2014.05.004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Berlowitz DR, Pugh MJ. Pharmacoepidemiology in community-dwelling elderly taking antiepileptic drugs. Int. Rev. Neurobiol.<\/i>, 81<\/b>, 153\u2013163 (2007).","DOI":"10.1016\/S0074-7742(06)81009-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Lee R, Lyles K, Sloane R, Colon-Emeric C. The association of newer anticonvulsant medications and bone mineral density. Endocr. Pract.<\/i>, 14<\/b> (aop), 1\u201322 (2012).","DOI":"10.4158\/EP12119.OR"},{"key":"15","unstructured":"15) Jett\u00e9 N, Lix LM, Metge CJ, Prior HJ, McChesney J, Leslie WD. Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch. Neurol.<\/i>, 68<\/b>, 107\u2013112 (2011)."},{"key":"16","unstructured":"16) Ensrud KE, Walczak TS, Blackwell TL, Ensrud ER, Barrett-Connor E, Orwoll ES. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology<\/i>, 71<\/b>, 723\u2013730 (2008)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Onodera K, Takahashi A, Mayanagi H, Wakabayashi H, Kamei J, Shinoda H. Phenytoin-induced bone loss and its prevention with alfacalcidol or calcitriol in growing rats. Calcif. Tissue Int.<\/i>, 69<\/b>, 109\u2013116 (2001).","DOI":"10.1007\/s00223-001-0020-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Hoshino M, Ikarashi N, Hirobe R, Hayashi M, Hiraoka H, Yokobori K, Ochiai T, Kusunoki Y, Kon R, Tajima M, Ochiai W, Sugiyama K. Effects of menthol on the pharmacokinetics of triazolam and phenytoin. Biol. Pharm. Bull.<\/i>, 38<\/b>, 454\u2013460 (2015).","DOI":"10.1248\/bpb.b14-00764"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Dominick MA, Robertson DG, Bleavins MR, Sigler RE, Bobrowski WF, Gough AW. Alpha 2u-globulin nephropathy without nephrocarcinogenesis in male Wistar rats administered 1-(aminomethyl)cyclohexaneacetic acid. Toxicol. Appl. Pharmacol.<\/i>, 111<\/b>, 375\u2013387 (1991).","DOI":"10.1016\/0041-008X(91)90244-9"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ling Q, Liu M, Wu MX, Xu Y, Yang J, Huang HH, Yu CX. Anti-allodynic and neuroprotective effects of koumine, a Benth alkaloid, in a rat model of diabetic neuropathy. Biol. Pharm. Bull.<\/i>, 37<\/b>, 858\u2013864 (2014).","DOI":"10.1248\/bpb.b13-00843"},{"key":"21","unstructured":"21) Gower AJ, Noyer M, Verloes R, Gobert J, Wulfert E. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol.<\/i>, 222<\/b>, 193\u2013203 (1992)."},{"key":"22","unstructured":"22) Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res.<\/i>, 28<\/b>, 2\u201317 (2013)."},{"key":"23","unstructured":"23) Collins N, Maher J, Cole M, Baker M, Callaghan N. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q. J. Med.<\/i>, 78<\/b>, 113\u2013122 (1991)."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, Pineau T, Saric J, Navarro F, Maurel P, Vilarem MJ. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J. Clin. Invest.<\/i>, 115<\/b>, 177\u2013186 (2005).","DOI":"10.1172\/JCI200521867"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Menon B, Harinarayan CV. The effect of anti epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism\u2013a longitudinal study. Seizure<\/i>, 19<\/b>, 153\u2013158 (2010).","DOI":"10.1016\/j.seizure.2010.01.006"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Fitzpatrick LA. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav.<\/i>, 5<\/b> (Suppl. 2), S3\u2013S15 (2004).","DOI":"10.1016\/j.yebeh.2003.11.026"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) V\u00e4lim\u00e4ki MJ, Tiihonen M, Laitinen K, T\u00e4htel\u00e4 R, K\u00e4rkk\u00e4inen M, Lamberg-Allardt C, M\u00e4kel\u00e4 P, Tunninen R. Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J. Bone Miner. Res.<\/i>, 9<\/b>, 631\u2013637 (1994).","DOI":"10.1002\/jbmr.5650090507"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology<\/i>, 70<\/b>, 1586\u20131593 (2008).","DOI":"10.1212\/01.wnl.0000310981.44676.de"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Tsukahara H, Kimura K, Todoroki Y, Ohshima Y, Hiraoka M, Shigematsu Y, Tsukahara Y, Miura M, Mayumi M. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr. Int.<\/i>, 44<\/b>, 247\u2013253 (2002).","DOI":"10.1046\/j.1442-200X.2002.01561.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Andress DL, Ozuna J, Tirschwell D, Grande L, Johnson M, Jacobson AF, Spain W. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch. Neurol.<\/i>, 59<\/b>, 781\u2013786 (2002).","DOI":"10.1001\/archneur.59.5.781"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA<\/i>, 285<\/b>, 785\u2013795 (2001).","DOI":"10.1001\/jama.285.6.785"},{"key":"32","unstructured":"32) Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev.<\/i>, 21<\/b>, 115\u2013137 (2000)."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Vestergaard P. Epilepsy, osteoporosis and fracture risk - a meta-analysis. Acta Neurol. Scand.<\/i>, 112<\/b>, 277\u2013286 (2005).","DOI":"10.1111\/j.1600-0404.2005.00474.x"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Recker RR, Kimmel DB, Dempster D, Weinstein RS, Wronski TJ, Burr DB. Issues in modern bone histomorphometry. Bone<\/i>, 49<\/b>, 955\u2013964 (2011).","DOI":"10.1016\/j.bone.2011.07.017"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Koo DL, Joo EY, Kim D, Hong SB. Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res.<\/i>, 104<\/b>, 134\u2013139 (2013).","DOI":"10.1016\/j.eplepsyres.2012.09.002"}],"container-title":["Biological & Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/11\/40_b17-00482\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T11:47:02Z","timestamp":1570276022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/11\/40_b17-00482\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b17-00482","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}